These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26134281)

  • 1. From qualified physician to licensed health care professional: the time has come to change mifepristone's label.
    Foster AM; Jackson CB; LaRoche KJ; Simmonds K; Taylor D
    Contraception; 2015 Sep; 92(3):200-2. PubMed ID: 26134281
    [No Abstract]   [Full Text] [Related]  

  • 2. Mifepristone label laws and trends in use: recent experiences in four US states.
    Sheldon WR; Winikoff B
    Contraception; 2015 Sep; 92(3):182-5. PubMed ID: 26116033
    [No Abstract]   [Full Text] [Related]  

  • 3. Updates to the US Food and Drug Administration Regulations for Mifepristone: Implications for Clinical Practice and Access to Abortion.
    Simmonds KE; Beal MW; Eagen-Torkko MK
    J Midwifery Womens Health; 2017 May; 62(3):348-352. PubMed ID: 28632953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Label for Mifepristone.
    Greene MF; Drazen JM
    N Engl J Med; 2016 Jun; 374(23):2281-2. PubMed ID: 27276566
    [No Abstract]   [Full Text] [Related]  

  • 5. Aligning mifepristone regulation with evidence: driving policy change using 15 years of excellent safety data.
    Cleland K; Smith N
    Contraception; 2015 Sep; 92(3):179-81. PubMed ID: 26093188
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.
    Hausknecht RU
    Ann Pharmacother; 2006 Apr; 40(4):785-6; author reply 786. PubMed ID: 16569806
    [No Abstract]   [Full Text] [Related]  

  • 7. Mifepristone (Mifeprex) label changes.
    Med Lett Drugs Ther; 2016 Apr; 58(1493):55-6. PubMed ID: 27101211
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of mifepristone abortions in clinical use.
    Henderson JT; Hwang AC; Harper CC; Stewart FH
    Contraception; 2005 Sep; 72(3):175-8. PubMed ID: 16102550
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Fuleihan C
    Am J Law Med; 2020 Nov; 46(4):507-517. PubMed ID: 33413017
    [No Abstract]   [Full Text] [Related]  

  • 10. Abortion pills: under whose control?
    Rowlands S
    J Fam Plann Reprod Health Care; 2012 Apr; 38(2):117-22. PubMed ID: 22454008
    [No Abstract]   [Full Text] [Related]  

  • 11. Refusal clauses and the weldon amendment: inherently unconstitutional and a dangerous precedent.
    Green J
    J Leg Med; 2005 Sep; 26(3):401-15. PubMed ID: 16126638
    [No Abstract]   [Full Text] [Related]  

  • 12. Mifepristone and misoprostol for early abortion.
    JNMA J Nepal Med Assoc; 2006; 45(161):I. PubMed ID: 17160090
    [No Abstract]   [Full Text] [Related]  

  • 13. If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion.
    Gold M; Chong E
    Contraception; 2015 Sep; 92(3):194-6. PubMed ID: 26093187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Her accidental legacy.
    Rosenberg D
    Newsweek; 2003 Oct; 142(15):64. PubMed ID: 16124192
    [No Abstract]   [Full Text] [Related]  

  • 15. Time to misoprostol after mifepristone: still a bone of contention!
    Rajaram S; Mehta S; Goel N
    BJOG; 2011 Apr; 118(5):629; author reply 629-30. PubMed ID: 21392227
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.
    Svedas E; Maciulaitis R; Stakisaitis D
    Ann Pharmacother; 2006 Apr; 40(4):784; author reply 784-5. PubMed ID: 16595574
    [No Abstract]   [Full Text] [Related]  

  • 17. Is there evidence to decrease the approved dose of 600 mg of mifepristone for medical abortion?
    Lièvre M; Sitruk-Ware R
    Contraception; 2010 Jun; 81(6):553-4. PubMed ID: 20472128
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical abortion.
    Crist T; Carhart L; Harrison W
    J Am Med Womens Assoc (1972); 2000; 55(4):243-4. PubMed ID: 10935362
    [No Abstract]   [Full Text] [Related]  

  • 19. [Medical abortion].
    Ottesen BS
    Ugeskr Laeger; 1999 May; 161(22):3263. PubMed ID: 10485201
    [No Abstract]   [Full Text] [Related]  

  • 20. When Off-label is Illegal: Implications of Mandating the FDA-approved Protocol for Mifepristone-induced Abortions.
    Britton L; Bryant A
    Womens Health Issues; 2015; 25(5):433-5. PubMed ID: 26169217
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.